<div id="readability-page-1"><p>Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising developments. Actinium’s ATNM-400, a targeted radiotherapy utilizing Actinium-225, has shown significant anti-tumor activity across various cancer types, including breast, lung, and prostate cancers. This includes effectiveness in treatment-resistant models, which positions Actinium as a leader in the radiopharmaceutical and antibody-drug conjugate sectors.<br/>Furthermore, the company is well-capitalized with a strong financial position, having $53.4 million in cash at the end of the third quarter of 2025, providing a solid runway for continued development. The undisclosed target of ATNM-400, which is associated with tumor progression and resistance, adds a layer of intrigue and potential for future growth. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.</p> <p>McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of <span>-7.8%</span> and a 37.42% success rate on recommended stocks. </p> <p>In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.</p></div>

ATNM

<p>Actinium Pharmaceuticals received a Buy rating from analyst Jason McCarthy of Maxim Group, with a $5.00 price target, due to promising developments in its ATNM-400 radiotherapy and strong financial position. The company has $53.4 million in cash, supporting future growth. H.C. Wainwright also reiterated a Buy rating with a $4.00 price target.</p>

Actinium Pharmaceuticals: Promising Developments and Strong Financial Position Drive Buy Rating